OPINION & CONTRIBUTED ARTICLES
Publisher's Platform: Food Safety - It's a Global Issue
Opinion

We Make Life Better with Nature's Best Solution®


The California Department of Public Health warned California residents not to eat certain bagged salads manufactured by River Ranch Fresh Foods, LLC due to potential contamination with Listeria monocytogenes on Friday.
According to a news release from CDPH, Salinas, California-based River Ranch Fresh Foods initiated a voluntary recall of bagged salads after routine sampling detected Listeria monocytogenes in two packages of shredded iceberg lettuce purchased from retail locations in California and Colorado. The recalled salad products were distributed nationwide to retail and foodservice outlets under various sizes and packaged under the brand names of River Ranch, Farm Stand, Hy-Vee, Marketside, Shurfresh, The Farmer's Market, Cross Valley, Fresh n Easy, Promark, and Sysco.
Although the bagged salads being recalled are no longer available for sale, CDPH issued a news release to warn consumers that they may have the recalled products in their homes. The agency published a list of all recalled products to aid consumers in identifying recalled products.
Anyone who finds recalled lettuce should discard it or return it to the point of purchase for a refund.
Symptoms of Listeria infection may include high fever, headache, and neck stiffness. Infants, the elderly, and people with weakened immune systems are at highest risk for severe illness and death. Listeria infection in pregnant women can lead to miscarriage or stillbirth, premature delivery, or infection of the newborn baby.
© Food Safety News
More Headlines from Food Recalls »LA MIRADA, CA--(Link Here to Press Release at Marketwire -05/15/12)- BioLargo, Inc. (OTC.BB: BLGO), creator of patented iodine technologies, today announced the development of novel antimicrobial products for the advanced wound care industry and the formation of a wholly owned subsidiary BioLargo Medical Group, Inc., formed to advance proof of claims and pursue regulatory approvals. To run the new subsidiary, BioLargo is assembling a team of experts to capitalize on the industry's demand for novel products. Unlike other iodine products, BioLargo's iodine is non-toxic, non-staining, and can be delivered on demand in precision dosing at much higher levels. For the medical field, this means incorporating one of the best antimicrobials known to man into wound care products in a way that is safe and non-staining.
"Armed with positive results from testing and field trials by veterinarians and hoof care specialists of our recently developed hoof and leg products for animals, it became increasingly apparent to us that our technology could play a pivotal role in the human wound care field," stated BioLargo's president, Dennis Calvert. "With the need for wound care products without microbial resistance so great, the commitment to this vertical market became the next logical and necessary step."
BioLargo's new products have achieved high levels of antimicrobial efficacy without cytotoxicity in lab tests and are being developed and refined in preparation for market introduction upon receiving appropriate regulatory approvals. BioLargo's CupriDyne® technology is green, and can be delivered in a liquid, gel or ointments.
BioLargo has made recent additions to the team with the anticipation of the formation of BioLargo Medical Group. Last year, Biolargo brought on board an experienced medical professional with an advanced wound care background, and has recently added another experienced wound care professional to assist with regulatory strategy and business development. The Company expects to continue to identify and recruit professionals from this field to assist in executing its business plan. "We are highly encouraged by the response from industry and believe our work in this area is both important and significant," stated Calvert.
Related Press Coverage Below:

BioLargo Inc. (OTCBB: BLGO), creator of patented iodine technologies, recently announced its entry into the wound care industry with the formation of a wholly owned subsidiary, BioLargo Medical Group, Inc. In today’s press release the company also announced the development of novel antimicrobial products for the wound care industry. The move could result in a higher valuation for its stock, as it competes alongside companies like Smith & Nephew plc (NYSE: SNN) (Market Cap $8.9Billion) and 3M Company (NYSE: MMM).
The company has been diligently assembling a team of industry experts to run the new subsidiary; last year the company brought on board an experienced medical professional with an advanced wound care background, and has recently added another experienced wound care professional to assist with regulatory strategy and business development.
With diseases resulting from antibiotic resistant bacteria on the rise, the wound care industry has an exceptionally great need for a product with no known microbial resistance. BioLargo’s new products have already achieved high levels of antimicrobial efficacy without cytotoxicity in lab tests, and as a result the company’s products are currently being developed and refined in preparation for market introduction, upon receiving appropriate regulatory approvals.
BioLargo’s president and CEO, Dennis Calvert, states “Armed with positive results from testing and field trials by veterinarians and hoof care specialists of our recently developed hoof and leg products for animals, it became increasingly apparent to us that our technology could play a pivotal role in the human wound care field. With the need for wound care products without microbial resistance so great, the commitment to this vertical market became the next logical and necessary step.”
Unlike other iodine products, the company’s iodine is non-toxic, non-staining, and can be delivered on demand in precision dosing at much higher levels than traditionally possible.
High-Value Focus Could Unlock Value
BioLargo’s new focus on the wound care industry could generate significant value for shareholders over the long-term. Medical device and technology companies tend to trade at higher price-earnings multiples than many other sectors. Moreover, these companies tend to trade with higher market capitalizations than other sectors prior to realizing any revenues.
Popular wound care companies include:
BioLargo’s inclusion into the wound care industry could result in a greater market capitalization, and eventually, a higher price-earnings multiple.

There's growing pressure for animal agriculture to change its practices, whether it be utilizing gestation crates or feeding antibiotics, but a new paper cautions that these changes may negatively impact food safety.
The discussion paper released by the Council for Agricultural Science and Technology -- a research group that includes the Farm Bureau and the American Veterinary Medical Association -- this week identified some of the factors now being discussed that impact animal health, including: antibiotic use, economies of scale, housing, local production and sustainability.
Scientists have long known there is a link between animal health, stress levels and pathogen shedding, but as CAST and others have noted, more research is needed.
"In addition to overtly ill animals, there is a growing body of evidence showing that chronically, previously, and not visibly ill animals are more likely to be contaminated with foodborne pathogens after processing in the abattoir (slaughterhouse)," the researchers write. "These animals, however, may go unnoticed during antemortem (live animal) inspection, and thus questions arise concerning the potential impacts of these animals entering the food supply on public health risk from foodborne pathogens."
The paper discusses past research that has found animals under stress or sick for a long period of time are more likely to carry key foodborne pathogens, especially Salmonella. Studies have also shown that animals with abscesses or "other significant lesions" that need extra trimming have a greater chance of being cross-contaminated because of the extra handling required.
Many of the buzzwords being discussed in the food movement, and by an increasing number of consumers: "organic," "all natural," "antibiotic-free," or "pastured" have direct animal health implications -- many sustainable food advocates argue that these changes lead to healthier animals. But CAST gives some examples of how these methods could have the opposite effect.
Under organic certification, for example, animals cannot be treated with antibiotics or synthetic worm drugs and if animals are based on pasture, these methods directly impact animal health and how production is managed. According to CAST researchers, "increased exposure to the soil and vermin may increase the prevalence of zoonotic diseases in livestock."
"Various policy changes may negatively impact animal health, resulting in more marginally or not visibly ill pigs, which tips the scales toward reduced public health," the authors write. "These proposed changes and their consequences need to be considered carefully."
The paper looks specifically at some research on the difference between keeping animals indoors vs. outdoors:
"Housing livestock indoors can also provide advantages in managing many foodborne organisms. Because outdoor environments cannot be cleaned or disinfected easily, pathogens can persist in the soil, standing water, outdoor structures, and other micro-environments, infecting successive generations of livestock. Other studies have shown that Campylobacter and Salmonella are more common in chickens having outdoor exposure than in birds raised in conventional indoor housing (cages). Dairy cows were shown to be at greater risk of subclinical mastitis when kept in outdoor environments compared with cows kept in barns. According to several studies, outdoor production can also promote infection of the zoonotic parasite Toxoplasma gondii in poultry and swine. This organism has been related in prenatal infections to death or severe brain and eye damage, especially where the mother has not been previously exposed and acquires an infection during her pregnancy." (Note: For research citations, see the full study).
Researchers also discuss using antibiotics in animal agriculture, a hot topic in the media:
"Antibiotics have a major, positive effect on improving animal and human health. They are used in human and veterinary medicine to treat and prevent disease. Antibiotic use in food animals is highly regulated by the U.S. Food and Drug Administration. The use of antibiotics in food-animal production, however, raises some concerns about antibiotic resistance in bacteria that could affect the efficacy of antibiotics in the treatment of human infections. Concern about antibiotic resistance is not equivalent to actual risk. Resistant bacteria were present long before antibiotics were discovered and found in many places without livestock exposure."
The FDA, however, has stated very clearly that certain "injudicious" antibiotic uses in agriculture are a public health risk. In its most recent guidance on the issue, the agency cited dozens of studies on antibiotic use and antibiotic resistance.
The full CAST paper, "The Direct Relationship between Animal Health and Food Safety Outcomes," can be read here.

What do Microsoft Corporation (NASDAQ: MSFT), Micromet Inc. (NASDAQ: MITI) and BioLargo Inc. (OTCBB: BLGO) have in common? The answer: A platform technology.
The Value of Platform Technologies
Platform technologies are defined as those technologies that enable the creation of products across multiple industries. Companies that develop these technologies are generally extremely profitable, since a single platform developed can target numerous vertical markets through licensing, joint ventures or simply traditional development.
There are two keys to successfully commercializing a platform technology. First, a company must have a game changing technology that has an economic driver, like increased market share or lower cost. And second, the company must help licensees see that the project risk has been reduced to an acceptable level to help justify the investment required to launch the products or services. In the end, this business model profits diversification and leveraged returns to investors.
Some Quintessential Case Studies
Microsoft Corporation (NASDAQ: MSFT) developed an operating system that enabled other companies to build software on top of it. By reducing the complexity of computer use for end users and encouraging developers to build software for its platform, the company gained enormous market share in the 1990’s and 2000’s that built its empire.
A more recent example of a platform technology is Micromet Inc. (NASDAQ: MITI), which was recently acquired by Amgen Inc. (NASDAQ: AMGN). Micromet developed a biotechnology platform that programs the body’s immune system to go after tumor cells. This single biotechnology could be applied to target many different forms of cancer.
BioLargo has the Key Ingredients
BioLargo Inc. (OTCBB: BLGO) is an up-and-coming company that has developed its own unique platform technology called CupriDyne®. By combining minerals with water from any source and delivering “free-iodine” on demand, in controlled dosages, the company could revolutionize several different industries by balancing efficacy with concerns about toxicity.
The company specializes in delivering iodine that is incorporated into products and systems for controlling odor, moisture and for disinfection. Its applications include water treatment and a host of medical products as well as all sorts of industrial and consumer applications.
The company has already entered into its first big deal with a major client, Central Garden & Pet Company that includes minimum purchase obligations and a promised national roll out. Amazingly the same technology that helps control odor and moisture in the pet industry looks to have game changing applications in the oil & gas, food & beverage, as well as, the medical & wound care industries.
Benefits for Investors & Shareholders
Platform technologies provide two key benefits for investors and shareholders. First, the large number of targeted end markets leads to greater diversification, which increases risk-adjusted returns over the long run. And second, the licensing aspect of the business model yields greater leverage, which means less capital outlay and greater free cash flow over time as the company continues to load its pipeline of products.
Companies that successfully develop platform technologies often benefit from higher price-earnings ratios, greater dividends and strong value creation for shareholders over the long term. Combined, these same aspects make up-and-coming platform technologies, like BioLargo’s CupriDyne® worthy of careful consideration by investors today.
This blog, found at www.BioLargo.blogspot.com (the “Blog”), is maintained by BioLargo, Inc., a Delaware corporation (“BioLargo”, or the “Company”). This Blog features both posts written by BioLargo, and links to third party articles posted on websites with no affiliation to BioLargo (which articles may or may not be reproduced partially or in their entirety in the Blog). BioLargo makes no assurance or guaranty of the accuracy of any information posted on this Blog, or contained in articles or web postings reposted on this Blog, or linked to by this Blog. Any opinions contained in articles or posts attributed to third parties are of the third party and not of BioLargo or its management. BioLargo makes no effort to verify or correct any inaccurate information authored by third parties and posted on this Blog. Any posts of this Blog should be read in conjunction with BioLargo’s filings with the Securities and Exchange Commission, which are available to the public at www.SEC.gov, or at www.BioLargo.com.
Information in this Blog may contain forward-looking statements. With respect to any such forward-looking statements posted authored by BioLargo and not a third party, such forward-looking statements are included in accordance with the safe harbor provisions of the private securities litigation reform act of 1995, and may involve known and unknown risks, uncertainties and other factors that may cause actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements. Although BioLargo’s management believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that actual results will not differ materially from these expectations. From time to time, these risks, uncertainties and other factors are discussed in our filings with the securities and exchange commission and can be found at www.SEC.gov.
NOTHING IN THIS BLOG OR ITS RELATED LINKS IS INTENDED TO CONSTITUTE AN OFFER TO BUY OR SELL SECURITIES.